Gene therapy demonstrates efficacy across nervous, muscular, circulatory, and immune systems in preclinical aging models, positioning it as a potential systemic intervention rather than a disease-specific treatment. The approach builds on established success in monogenic disorders like progeria and neurodegenerative diseases to target fundamental aging mechanisms. This represents a paradigm shift from treating individual age-related diseases to addressing core aging processes simultaneously. The multi-organ benefits suggest gene therapy could deliver the holy grail of aging research: coordinated rejuvenation across physiological systems. However, significant translation barriers remain formidable. Immunogenicity concerns, off-target effects, and complex regulatory frameworks create substantial hurdles for human application. The fragmented nature of current research also limits comprehensive understanding of optimal targets and delivery methods. While promising, this field requires coordinated large-scale studies to identify the most effective genetic interventions and overcome safety concerns. The regulatory pathway for aging-focused gene therapy remains undefined, as aging itself isn't classified as a disease. Success will likely require unprecedented collaboration between researchers, regulators, and industry to establish new therapeutic frameworks for healthspan extension.